Clinical Trials Logo
  1. Home
  2. Neoplasms, Breast
  3. NCT00105950

Study Of Lapatinib In Patients With Relapsed Or Refractory Inflammatory Breast Cancer

Neoplasms, Breast Clinical Trial

Official title:
A Phase II Study to Evaluate the Efficacy, Safety and Pharmacodynamics of Lapatinib in Patients With Relapsed or Refractory Inflammatory Breast Cancer

Clinical Trial Summary

This study was designed to determine how effective and safe a new investigational drug, lapatinib, is in treating patients with treatment refractory or relapsed inflammatory breast cancer. Tumor tissue collected pre-treatment and at Day 28 will be examined for biologic activity by IHC (immunohistochemistry). Treatment will consist of daily oral therapy with lapatinib. A patient may continue treatment as long as they are receiving benefit. Blood samples for hematology and chemistry panels, MUGA/ECHO (multigated acquisition/echocardiogram) exams and physical exams will be performed throughout the study to monitor safety.

Clinical Trial Description

This Phase II open label, multicenter study is designed to evaluate the efficacy, safety, and pharmacodynamic effects of oral lapatinib administered as a single agent therapy to patients with relapsed or refractory inflammatory breast cancer. Eligible patients must have a diagnosis of inflammatory breast cancer based on clinicopathologic criteria, tumor that is readily accessible for biopsy, and must have previously received treatment with an anthracycline and taxane-containing regimen (30 patients) plus trastuzumab (90 patients). Patients enrolled must have tumors that overexpress ErbB2, with or without co-expression of ErbB1. The primary objective for this study is to evaluate the objective response rate (defined as complete response plus partial response). Secondary objectives are to evaluate clinical benefit including quality of life parameters, progression-free survival, overall survival, time-to-response, response duration, safety and tolerability, pharmacodynamic effects on intracellular mediators that regulate tumor cell growth and survival, as well as effects on proteomic profile, and circulating levels of extracellular domains of ErbB1 and ErbB2 in peripheral blood. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT00105950
Study type Interventional
Source GlaxoSmithKline
Contact
Status Completed
Phase Phase 2
Start date March 2005
Completion date May 2010
View Details
See also
  Status Clinical Trial Phase
Terminated NCT00251433 - GW572016 With Docetaxel and Trastuzumab for the Treatment Of Untreated ErbB2 Over-Expressing Metastatic Breast Cancer Phase 1
Completed NCT01271738 - Evaluating and Comparing Two Surgical Methods for Treatment of Early Stage Breast Cancer N/A
Recruiting NCT04892342 - Study of ESG401 in Adults With Solid Tumors Phase 1/Phase 2
Terminated NCT02213042 - Evaluation of Biomarkers Associated With Response to Subsequent Therapies in Subjects With HER2-Positive Metastatic Breast Cancer Phase 2
Withdrawn NCT01137994 - A Phase II, Randomized, Open-label Study of Lapatinib Plus Chemotherapy Versus Trastuzumab Plus Chemotherapy in HER2-positive and p95HER2-positive Metastatic Breast Cancer Phase 2
Completed NCT00790816 - Continuation Study of Lapatinib Monotherapy or Lapatinib in Combination With Other Anti-cancer Agents Phase 1
Completed NCT00051103 - Oral Drug Study In Women With Refractory Metastatic Breast Cancer After First-line or Second-line Herceptin. Phase 2
Completed NCT00320411 - GW572016 In Patients With ErbB2 Over - Expressing Advanced Or Metastatic Breast Cancer Phase 2
Completed NCT00258050 - To Examine The Effects Of Lapatinib On Orally And Intravenously Administered Midazolam In Cancer Patients Phase 1
Terminated NCT01498588 - Trial of Eribulin Followed by Doxorubicin & Cyclophosphamide for Her2-negative, Locally Advanced Breast Cancer Phase 2
Terminated NCT00479856 - Lapatinib In Combination With Chemotherapy In Subjects With Relapsed Breast Cancer Phase 2
Completed NCT00320385 - Lapatinib In Combination With Trastuzumab Versus Lapatinib Monotherapy In Subjects With HER2-positive Metastatic Breast Cancer Phase 3
Completed NCT00062686 - GW572016 For Treatment Of Refractory Metastatic Breast Cancer Phase 2
Completed NCT00996762 - A Study in Cancer Patients to Evaluate the Bioequivalence of Alternative Formulations of Lapatinib Phase 1
Terminated NCT02913729 - Pre- Versus Postoperative Accelerated Partial Breast Irradiation N/A
Completed NCT01160211 - A Study to Compare the Safety and Efficacy of an Aromatase Inhibitor in Combination With Lapatinib, Trastuzumab or Both for the Treatment of Hormone Receptor Positive, HER2+ Metastatic Breast Cancer Phase 3
Recruiting NCT05814224 - Monitoring luminAl Breast Cancer Through the Evaluation of Mutational and epiGeNEtic alteraTIons of Circulating ESR1 DNA N/A
Completed NCT01815294 - A Pivotal Bioequivalence Study of DOXIL/CAELYX (Doxorubicin HCL) in Patients With Advanced or Refractory Solid Malignancies Including Patients With Ovarian Cancer Phase 1
Terminated NCT00437073 - Brain Metastases In ErbB2-Positive Breast Cancer Phase 2
Completed NCT00356811 - Lapatinib Combined With Paclitaxel For Patients With First-Line ErbB2-Amplified Metastatic Breast Cancer Phase 2